EGLN1 — Egl-9 Family Prolyl Hydroxylase 1

Overview

flowchart TD
    EGLN1["EGLN1"] -->|"interacts with"| Ms["Ms"]
    EGLN1["EGLN1"] -->|"activates"| Cancer["Cancer"]
    EGLN1["EGLN1"] -->|"interacts with"| Tumor["Tumor"]
    EGLN1["EGLN1"] -->|"associated with"| Cancer["Cancer"]
    EGLN1["EGLN1"] -->|"associated with"| GENES["GENES"]
    EGLN1["EGLN1"] -->|"regulates"| RNA["RNA"]
    EGLN1["EGLN1"] -->|"regulates"| AND["AND"]
    EGLN1["EGLN1"] -->|"interacts with"| cancer["cancer"]
    EGLN1["EGLN1"] -->|"interacts with"| GENES["GENES"]
    EGLN1["EGLN1"] -->|"interacts with"| RNA["RNA"]
    EGLN1["EGLN1"] -->|"interacts with"| COLORECTAL_CANCER["COLORECTAL CANCER"]
    EGLN1["EGLN1"] -->|"regulates"| Microbiota["Microbiota"]
    EGLN1["EGLN1"] -->|"regulates"| Gut_Microbiota["Gut Microbiota"]
    CANCER["CANCER"] -->|"activates"| EGLN1["EGLN1"]
    style EGLN1 fill:#4fc3f7,stroke:#333,color:#000

EGLN1 (Egl-9 Family Prolyl Hydroxylase 1) encodes Prolyl Hydroxylase 2 (PHD2), the principal oxygen sensor regulating hypoxia-inducible factor-alpha (HIF-alpha) stability. EGLN1 is the most important prolyl hydroxylase for HIF regulation under physiological conditions and serves as a critical link between cellular oxygen sensing and adaptive gene expression. Variants in EGLN1 cause congenital erythrocytosis (polycythemia) and have been implicated in Alzheimer’s disease and Parkinson’s disease through dysregulated hypoxia response pathways

Gene Overview

Protein Structure

Domain Architecture

PHD2 is a ~426 amino acid protein with a catalytic domain and regulatory regions:

• N-terminal domain: Substrate binding and oxygen sensing

• catalytic core: Contains the 2-oxoglutarate (2-OG) binding site

• C-terminal region: Regulatory functions and VHL interaction

Catalytic Mechanism

PHD2 is a 2-oxoglutarate (2-OG)-dependent dioxygenase that requires:

• Iron (Fe²⁺): Essential cofactor in the active site

• 2-oxoglutarate: Cosubstrate converted to succinate

• Molecular oxygen: Substrate for hydroxylation

• Ascorbate: Reducing agent for iron

The reaction:

HIF-α + O₂ + 2-OG → HIF-α(OH) + succinate + CO₂

Regulatory Features

PHD2 activity is modulated by:

1. Oxygen concentration: Direct sensing mechanism

2. Iron availability: Essential cofactor

3. 2-OG levels: Metabolic status indicator

4. Succinate accumulation: Product inhibition

5. Nitric oxide: Negative regulation

6. Reactive oxygen species: Oxidative regulation

Enzymatic Function

HIF-α Hydroxylation

PHD2 hydroxylates specific proline residues on HIF-α subunits:

• Pro402 (HIF-1α): Major hydroxylation site

• Pro564 (HIF-1α): Secondary site

• Pro405/Pros566 (HIF-2α): Conserved sites

Hydroxylation creates the binding site for the von Hippel-Lindau (VHL) tumor suppressor protein.

VHL Recognition and Degradation

The hydroxylated HIF-α binds to the VHL E3 ubiquitin ligase complex, leading to:

1. Polyubiquitination of HIF-α

2. Proteasomal degradation

3. Prevents transcriptional activation

Under hypoxia, PHD2 activity decreases, HIF-α escapes hydroxylation, dimerizes with HIF-β, and activates hundreds of target genes.

Alternative Substrates

Beyond HIF-α, PHD2 hydroxylated:

• IKKβ: NF-κB pathway regulation

• RBPJ: Notch signaling

• OSTM1: Bone metabolism

Tissue Distribution

Brain Expression

EGLN1 is expressed throughout the brain:

• Neurons: High expression in cortical and hippocampal neurons

• Astrocytes: Moderate expression

• Microglia: Variable expression with activation state

• Oligodendrocytes: Lower expression

Regional Specificity

Peripheral Expression

• Kidney: Highest expression (erythropoietin regulation)

• Heart: High (cardiac adaptation)

• Liver: Moderate

• Skeletal muscle: Variable with oxygen supply

HIF Signaling

Canonical HIF Pathway

HIF is a heterodimeric transcription factor:

• HIF-α subunits: HIF-1α, HIF-2α (EPAS1), HIF-3α

• HIF-β subunit: Constitutively expressed (ARNT)

HIF target genes regulate:

• Angiogenesis: VEGF, FLT1

• Erythropoiesis: EPO

• Metabolism: GLUT1, PDK1

• Cell survival: BNIP3, REDD1

Non-Canonical Functions

HIF also regulates:

• Mitochondrial dynamics: PGC-1α, mitophagy

• Immune function: Cytokine production

• Stem cell biology: Notch, Wnt pathways

Disease Associations

Congenital Erythrocytosis

EGLN1 gain-of-function mutations cause:

• Elevated hemoglobin: Increased RBC production

• High hematocrit: Blood viscosity concerns

• Thrombosis risk: Vascular complications

• Secondary polycythemia: Without JAK2 mutation

The mechanism: increased PHD2 activity leads to enhanced HIF degradation, reducing EPO production feedback.

Alzheimer’s Disease

EGLN1/PHD2 is implicated in AD through multiple mechanisms^{1HIF signaling in Alzheimer's disease2017 · Nat Rev Neurosci · PMID 28986513Open reference}:

Hypoxia Response Dysregulation

• Reduced HIF activity in AD brains despite hypoxia

• Impaired adaptive response to cerebral hypoperfusion

• Accumulation of dysfunctional PHD2

Amyloid-beta Effects

• Aβ inhibits PHD2 function

• Disrupts oxygen sensing in neurons

• Creates vicious cycle of hypoxia response failure

Cerebral Blood Flow

• Impaired HIF-VEGF axis affects angiogenesis

• Reduced vascular maintenance

• Contributes to vascular dysfunction

Therapeutic Implications

• PHD2 inhibitors in clinical trials for AD

• Enhancing HIF may protect neurons

• Improving cerebral blood flow

Parkinson’s Disease

In PD, EGLN1/PHD2 is relevant through^{2Hypoxia and Parkinson's disease vulnerability2018 · J Neurosci · PMID 29899370Open reference}:

Dopaminergic Neuron Vulnerability

• Substantia nigra has high metabolic demand

• Limited oxygen supply in PD brain

• Impaired hypoxia response accelerates degeneration

Mitochondrial Function

• HIF regulates PGC-1α and mitochondrial biogenesis

• Dysregulated HIF leads to mitochondrial dysfunction

• Energy failure in dopaminergic neurons

Neuroinflammation

• HIF modulates microglial inflammatory responses

• Dysregulated PHD2 affects cytokine production

• May contribute to chronic neuroinflammation

Therapeutic Target

• PHD2 inhibitors show neuroprotection in models

• Enhancing HIF may support dopaminergic survival

• Clinical trials in development

Cancer

Paradoxically, EGLN1/PHD2 is also relevant in cancer:

• Tumor hypoxia activates HIF

• Promotes angiogenesis and metastasis

• PHD2 as therapeutic target

• Some tumors have EGLN1 mutations

Molecular Mechanisms

Oxygen Sensing

PHD2 senses oxygen through its catalytic mechanism:

1. Oxygen-dependent catalysis: Hydroxylation requires O₂

2. Fe²⁺ oxidation: Inactivates enzyme under high O₂

3. Metabolic coupling: 2-OG levels reflect cellular energy

This directly links oxygen to gene regulation.

Cross-Talk with Other Pathways

mTOR Signaling

PHD2 and mTOR pathway interact:

• mTOR regulates HIF translation

• PHD2 activity affects mTOR signaling

• Feedback loops in neuronal survival^{3EGLN1 regulates mTOR signaling in neurons2019 · Nat Neurosci · PMID 31110361Open reference}

NF-κB Pathway

• IKKβ is a PHD2 substrate

• Cross-talk between hypoxia and inflammation

• Implications for neuroinflammation

Cellular Consequences

Dysregulated EGLN1 leads to:

• Altered metabolic adaptation

• Impaired stress response

• Mitochondrial dysfunction

• Increased apoptosis susceptibility

Therapeutic Implications

PHD Inhibitors

PHD inhibitors are in development for multiple conditions^{4PHD inhibitors in clinical development2015 · Nat Rev Drug Discov · PMID 25681701Open reference}:

Anemia Treatment

• Stimulate endogenous erythropoietin

• Oral administration vs. injections

• In phase 3 trials for CKD anemia

Neuroprotection

• Cross blood-brain barrier in some compounds

• Protect against stroke

• Potential for AD and PD

Anti-Angiogenic Therapy

• Inhibit tumor hypoxia response

• Combined with chemotherapy

• In cancer clinical trials

Challenges

• Balancing HIF activation in different tissues

• Long-term effects of chronic HIF elevation

• Off-target effects

• Delivery to specific brain regions

Expression in Disease States

Alzheimer’s Disease Brain

• Reduced PHD2 expression in cortex

• Impaired HIF activation despite hypoxia

• Correlation with disease severity

• Therapeutic opportunity

Parkinson’s Disease Brain

• Altered PHD2 in substantia nigra

• Dysregulated HIF response

• May contribute to neuronal loss

• PHD2 as biomarker

Activated Microglia

• Increased EGLN1 expression

• Role in inflammatory response

• Potential therapeutic target

Animal Models

Knockout Mice

Egln1 knockout is embryonic lethal:

• Severe anemia

• Cardiac defects

• Impossible to study adult neurons

Conditional Knockout

Neuron-specific deletion shows:

• Enhanced HIF activation

• Reduced infarct size in stroke

• Protection in some neurodegeneration models

Transgenic Models

• Overexpression of PHD2: impaired hypoxia response

• Dominant negative: constitutive HIF

• Useful for therapeutic screening

Clinical Relevance

Genetic Testing

EGLN1 testing is indicated for:

• Unexplained polycythemia

• Familial erythrocytosis

• Suspected congenital disorder

Biomarkers

• EGLN1 expression as tissue hypoxia marker

• PHD2 activity in disease states

• Potential for disease monitoring

Therapeutic Development

Drug Candidates

• Multiple PHD2 inhibitors in trials

• Brain-penetrant compounds in development

• Combination therapies

Clinical Trials

• Anemia: Phase 3 completed

• Stroke: Phase 2 ongoing

• Neurodegeneration: Planning stages

Research Directions

Current Questions

1. Cell-type specificity: How does EGLN1 function differ across neurons, glia?

2. Disease modification: Can EGLN1 modulation alter disease progression?

3. Biomarkers: Can EGLN1 serve as a disease biomarker?

4. Therapeutic window: What’s the optimal level of HIF activation?

Emerging Areas

• Single-cell analysis: Cell-type specific EGLN1 function

• Spatial transcriptomics: Regional brain patterns

• iPSC models: Patient-specific disease mechanisms

• Gene therapy: Targeting approaches

Interactions and Pathways

Protein Partners

Signaling Pathways

• HIF pathway: Primary downstream effects

• mTOR pathway: Cross-talk

• NF-κB pathway: Inflammatory regulation

• NOTCH pathway: Developmental regulation

See Also

• Hypoxia-Inducible Factor

• Alzheimer’s Disease Mechanisms

• Parkinson’s Disease Mechanisms

• VHL Gene

• EPO and Neuroprotection

External Links

• NCBI Gene: EGLN1

• UniProt: Q9Y2H5

• Ensembl: ENSG00000127837

• OMIM: 609424

• GeneCards: EGLN1